Evaluating the effect of Tocilizumab on the recovery of severe Covid-19 patients Hospitalization in the cardiorespiratory intensive care unit (ICU)

Introduction and aim: In the severe form of Covid 19, the vital organs of the body experience dysfunction such as respiratory distress, which may eventually lead to the death of the patient. The present study was conducted with the aim of investigating the effect of Actmera drug on the recovery of patients suffering from the severe form of Covid-19 disease. Materials and methods: The present study was a retrospective cohort study. which was done in Kamkar Hospital in the summer of 2021. The studied data include age, sex, underlying disease, severity of pulmonary involvement, blood oxygen saturation percentage, duration of hospitalization, need for mechanical ventilation, etc. candidate countries to receive Actmera drug, were extracted and compared.. Results: 70 patients (50%) were male and 70 patients (50%) were female. The average age of the patients was 55.96±14.18. Clinical symptoms, the average number of days dependent on a ventilator, the number of days receiving oxygen with a reserve bag and the number of days receiving nasal, the number of days hospitalized in the normal department, in the special care departments, as well as the OUTCOME of the patients did not have a statistically significant difference between the two groups (P >0.05). Among the laboratory variables of lymph flow, lactate dehydrogenase was not statistically significantly different between the two groups (P>0.05). But the course of CRP level had a statistically significant difference (P<0.05). There was a statistically significant difference in blood oxygen saturation percentage in room air and blood oxygen saturation with auxiliary oxygen between the two groups (P<0.05). Conclusion: The results showed that the drug Actmera was effective in the course of recovery and increasing the amount of blood lymphocytes and blood oxygen of the patients, but it did not have much effect in reducing the need for special care and the outcome of death. For this reason, there is a need for more clinical trials to prove the effectiveness of the drug.

Evaluating the effect of Tocilizumab on the recovery of severe Covid-19 patients Hospitalization in the cardiorespiratory intensive care unit (ICU) Keywords:

Covid 19 , Tocilizumab , ARDS , Intensive care unit